tripalmitoyl cysteine has been researched along with Lyme Disease in 1 studies
*Lyme Disease: An infectious disease caused by a spirochete, BORRELIA BURGDORFERI, which is transmitted chiefly by Ixodes dammini (see IXODES) and pacificus ticks in the United States and Ixodes ricinis (see IXODES) in Europe. It is a disease with early and late cutaneous manifestations plus involvement of the nervous system, heart, eye, and joints in variable combinations. The disease was formerly known as Lyme arthritis and first discovered at Old Lyme, Connecticut. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heilbrun, M; Kirschning, CJ; Ma, Y; Philipp, MT; Wang, X; Weis, JH; Weis, JJ; Wooten, RM; Yoder, A | 1 |
1 other study(ies) available for tripalmitoyl cysteine and Lyme Disease
| Article | Year |
|---|---|
Tripalmitoyl-S-glyceryl-cysteine-dependent OspA vaccination of toll-like receptor 2-deficient mice results in effective protection from Borrelia burgdorferi challenge.
Topics: Animals; Antibodies, Bacterial; Antigens, Surface; Bacterial Outer Membrane Proteins; Bacterial Vaccines; Cysteine; Lipoproteins; Lyme Disease; Membrane Glycoproteins; Mice; Mice, Inbred C3H; Receptors, Cell Surface; Toll-Like Receptor 2; Toll-Like Receptors; Vaccination | 2003 |